 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...8182838485868788899091...235236» |
- |||| 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial https://t.co/NrkP2CuumN (Twitter) - Aug 11, 2022
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS
I tweeted about this: Some reasons (excuses) to give FOLFOX+NIVO regardless of CPS score: -Canada and Japan are doing it -Can't be 1,000% sure pt is PD-L1 neg -It’s a protein test that degrades over time & its operator dependent (Twitter) - Aug 11, 2022
- || Vyloy (zolbetuximab-clzb) / Astellas
Biomarker, Trial completion date, Trial primary completion date, Monotherapy: ILUSTRO: A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer (clinicaltrials.gov) - Aug 11, 2022
P2, N=116, Recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Trial completion date: Feb 2023 --> Jul 2024 | Trial primary completion date: Jul 2022 --> Apr 2024
- | Journal: Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. (Pubmed Central) - Aug 11, 2022
Trial completion date: Feb 2023 --> Jul 2024 | Trial primary completion date: Jul 2022 --> Apr 2024 Organ preservation is achievable in half of the patients with rectal cancer treated with total neoadjuvant therapy, without an apparent detriment in survival, compared with historical controls treated with chemoradiotherapy, TME, and postoperative chemotherapy.
- ||| 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
P2/3 data, Journal: A randomized controlled trial comparing perioperative vs. postoperative mFOLFOX6 for lower rectal cancer with suspected lateral pelvic lymph node metastasis (JCOG1310): a phase II/III randomized controlled trial. (Pubmed Central) - Aug 11, 2022
Organ preservation is achievable in half of the patients with rectal cancer treated with total neoadjuvant therapy, without an apparent detriment in survival, compared with historical controls treated with chemoradiotherapy, TME, and postoperative chemotherapy. Perioperative mFOLFOX6 may be an insufficient treatment to improve survival of lower rectal cancer with lateral pelvic lymph node metastasis.
- || Herceptin (trastuzumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
Review, Journal: News in gastrointestinal radiotherapy: The esophageal cancer (Pubmed Central) - Aug 11, 2022
Pre-operative chemotherapy with Paclitaxel-Carboplatin followed by adjuvant immunotherapy with Nivolumab represents a major advance in the management of locally advanced oesophageal cancer...Several trials are currently ongoing to evaluate the benefit of immunotherapy in non-operable cancers. In contrast, dose escalation in locally advanced non-operable tumors and the combination of pre-operative chemo-radiotherapy with trastuzumab have not been shown to be beneficial.
- | Journal: Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance). (Pubmed Central) - Aug 10, 2022
In contrast, dose escalation in locally advanced non-operable tumors and the combination of pre-operative chemo-radiotherapy with trastuzumab have not been shown to be beneficial. Among patients with stage III colon cancer enrolled in a trial of postoperative treatment, larger volumes of recreational physical activity, longer durations of light- to moderate-intensity aerobic physical activity, or any vigorous-intensity aerobic physical activity were associated with the greatest improvements in DFS.
- | 5-fluorouracil / Generic mfg.
Journal: Second Cancer After Additive Chemotherapy in Patients With Colon Cancer. (Pubmed Central) - Aug 10, 2022
Novelty and Impact Statement To our knowledge, this is the first population-based study analyzing second cancer development after additive chemotherapy in patients with UICC III-IV colon cancer. The results have an important impact on the surveillance and long-term follow-up of cancer patients.
- || simmitecan / HaiHe Biopharma
P1 data, Journal, Combination therapy: A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil/Leucovorin or Thalidomide in Patients With Advanced Solid Tumor. (Pubmed Central) - Aug 10, 2022
Simmitecan + 5-FU/LV regimen seemed to have a better efficacy. Nonetheless, the efficacy of this regimen needs to be further explored in the subsequent study.
- || leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Review, Journal: Ten-Year Review of Gestational Trophoblastic Disease at Lady Reading Hospital, Peshawar. (Pubmed Central) - Aug 10, 2022
The frequency of GTD was 3.4/1000 pregnancies. Complete mole was the most frequent lesion, and single-agent chemotherapy had a good outcome in low- and high-risk patients with a risk score of 7-9 (with no evidence of metastasis, prior chemotherapy, or choriocarcinoma and FIGO stage 1).
- |||| Ampligen (rintatolimod) / AIM ImmunoTech
New P2 trial: Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC (clinicaltrials.gov) - Aug 10, 2022
P2, N=90, Not yet recruiting, Sponsor: AIM ImmunoTech Inc.
- ||||| 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: 🎥 @ChiaraCrem1 of @Unipisa talks on mFOLFOXIRI/PAN vs mFOLFOX6/PAN as initial treatment of patients with unresectable RAS & BRAF WT mCRC Watch: 👉https://t.co/ZJdFC9j2yS👈 @ASCO #ASCO22 (Twitter) - Aug 9, 2022
- leucovorin calcium / Generic mfg.
Antibacterial activity of propargyl-linked antifolates against uropathogens in urinary tract infections under test conditions that mimic the infection sites (Virtual-only (Zoom)) - Aug 9, 2022 - Abstract #ACSFall2022ACS_Fall_13145;
Herein, we will present the antibacterial activity of PLAs against major uropathogens at low pH, folinic acid, and synthetic urine conditions that prevail in UTIs. Structural features of PLAs that render enhanced antibacterial activity at low pH will also be discussed.
- | Trial primary completion date, Surgery: PANCREAS: Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery (clinicaltrials.gov) - Aug 9, 2022
P2, N=30, Recruiting, Sponsor: Hamilton Health Sciences Corporation
Structural features of PLAs that render enhanced antibacterial activity at low pH will also be discussed. Trial primary completion date: May 2022 --> May 2024
- | Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date, Surgery: Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer (clinicaltrials.gov) - Aug 9, 2022
P2, N=17, Active, not recruiting, Sponsor: University of Southern California
Trial primary completion date: May 2022 --> May 2024 Trial completion date: Dec 2022 --> Jun 2023 | Trial primary completion date: Dec 2021 --> Jun 2022
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Zepsun (donafenib) / Suzhou Zelgen
New P2 trial: HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC (clinicaltrials.gov) - Aug 9, 2022
P2, N=93, Not yet recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- ||||| Clinical, P3 data: ► Presentation: - Panitumumab + mFOLFOX6 Vs Bevacizumab + Mfolfox6 as 1st line Treatment in Patients with RAS Wild-type Metastatic Colorectal Cancer (mCRC) ：Results From the Phase 3 PARA-DIGM Trial Dr. Takayuki Yoshino, Japan National Cancer Center Hospital East @KoheiShitara (Twitter) - Aug 8, 2022
- || Thank you for this; my brother had Whipple last year, 12 rounds FOLFIRINOX, recurred 4 months post chemo, now on Gemzar/Abraxane. I'm very happy you had such a good outcome. (Twitter) - Aug 8, 2022
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Review, Journal, Combination therapy: Formulation of two lipid-based membrane-core nanoparticles for FOLFOX combination therapy. (Pubmed Central) - Aug 7, 2022
The procedures for Nano-Folox and Nano-FdUMP take ~17 h and ~4 h, respectively (~17 h if they are prepared simultaneously). Procedures for the physicochemical (~30 h) and cytotoxic (~54 h) characterization are also described.
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Retrospective data, Journal, Real-world evidence: Efficacy and safety of the combination of nano-liposomal irinotecan and 5-fluorouracil/l-leucovorin in unresectable advanced pancreatic cancer: A real-world study. (Pubmed Central) - Aug 7, 2022
Procedures for the physicochemical (~30 h) and cytotoxic (~54 h) characterization are also described. Nal-IRI + 5-FU/l-LV therapy was considered to be a useful regimen as second-line or later treatment for unresectable advanced pancreatic cancer, even in clinical practice.
- || methotrexate IV / Generic mfg., leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Review, Journal: Leucovorin (folinic acid) rescue for high-dose methotrexate: A review. (Pubmed Central) - Aug 6, 2022
Nonetheless, leucovorin rescue protocols differ greatly across tumour types and medical institutions. Further studies are needed to investigate the optimal dosage regimen for leucovorin rescue in various tumours using HDMTX.
- | 5-fluorouracil / Generic mfg.
Journal, Real-world evidence: Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. (Pubmed Central) - Aug 6, 2022
Patients treated with FOLFIRI received the highest dose of pegfilgrastim to manage neutropenia. The results of this real-world analysis are consistent with prior evaluations of patients with mPDAC and highlight the importance of managing adverse events and associated cost implications.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, Clinical, Journal: Precision medicine in pancreatic cancer: Patient derived organoid pharmacotyping is a predictive biomarker of clinical treatment response. (Pubmed Central) - Aug 6, 2022
Sequencing PDOs following biomass expansion improves clinical sequencing quality. High in-vitro sensitivity to standard-of-care chemotherapeutics predicts good clinical response to systemic chemotherapy in PDAC.
- | Journal, HEOR, Real-world evidence: Real-world cost-effectiveness of first-line gemcitabine + nab-paclitaxel versus FOLFIRINOX in patients with advanced pancreatic cancer. (Pubmed Central) - Aug 6, 2022
High in-vitro sensitivity to standard-of-care chemotherapeutics predicts good clinical response to systemic chemotherapy in PDAC. Gem-Nab is likely more costly and less effective than FOLFIRINOX and therefore not considered cost-effective at commonly accepted willingness-to-pay thresholds.
- ||||| Clinical, P3 data: ► Presentation: - Panitumumab + mFOLFOX6 Vs Bevacizumab + Mfolfox6 as 1st line Treatment in Patients with RAS Wild-type Metastatic Colorectal Cancer (mCRC) ：Results From the Phase 3 PARA-DIGM Trial Dr. Takayuki Yoshino, Japan National Cancer Center Hospital East @KoheiShitara (Twitter) - Aug 5, 2022
- | AiTan (rivoceranib) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial: HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma (clinicaltrials.gov) - Aug 5, 2022
P=N/A, N=43, Completed, Sponsor: Sun Yat-sen University
- ||||| Datroway (datopotamab deruxtecan) / Daiichi Sankyo, AstraZeneca
New P2 trial, Monotherapy, Pan tumor: Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) (clinicaltrials.gov) - Aug 5, 2022
P2, N=451, Not yet recruiting, Sponsor: AstraZeneca
- || Graspa (eryaspase) / PHAXIAM Therap
Enrollment closed, Trial primary completion date: Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Aug 5, 2022
P1, N=19, Active, not recruiting, Sponsor: Georgetown University
Gem-Nab is likely more costly and less effective than FOLFIRINOX and therefore not considered cost-effective at commonly accepted willingness-to-pay thresholds. Recruiting --> Active, not recruiting | Trial primary completion date: May 2022 --> May 2023
- || Avastin (bevacizumab) / Roche
P2 data, Journal: A multicenter phase II trial evaluating the efficacy of bevacizumab plus mFOLFOX6 for R0 surgical resection in advanced colorectal liver metastases harboring mutant-type KRAS: NEXTO-mt trial. (Pubmed Central) - Aug 5, 2022
Recruiting --> Active, not recruiting | Trial primary completion date: May 2022 --> May 2023 For advanced CRLMs harboring mutant-type KRAS, bevacizumab plus mFOLFOX6 achieved a high R0 resection rate, leading to favorable survival.
- | Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly
Trial primary completion date: AVETRIC: AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Aug 4, 2022
P2, N=58, Active, not recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
For advanced CRLMs harboring mutant-type KRAS, bevacizumab plus mFOLFOX6 achieved a high R0 resection rate, leading to favorable survival. Trial primary completion date: May 2022 --> Dec 2022
- ||| Lonsurf (trifluridine/tipiracil) / Otsuka
Trial completion date, Trial initiation date: ERASE-CRC: Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients (clinicaltrials.gov) - Aug 4, 2022
P2, N=300, Not yet recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
Trial primary completion date: May 2022 --> Dec 2022 Trial completion date: Mar 2027 --> Dec 2027 | Initiation date: May 2022 --> Dec 2022
- || Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Metastases: AtezoTRIBE: FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Aug 4, 2022
P2, N=201, Active, not recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
Trial completion date: Mar 2027 --> Dec 2027 | Initiation date: May 2022 --> Dec 2022 Trial completion date: Apr 2021 --> Dec 2022
- || ompenaclid (RGX-202) / Inspirna, EMD Serono
Trial completion date, Trial primary completion date, Combination therapy, Metastases: RGX-202-001: A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer (clinicaltrials.gov) - Aug 4, 2022
P1, N=60, Recruiting, Sponsor: Inspirna, Inc.
Trial completion date: Apr 2021 --> Dec 2022 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: May 2023 --> Dec 2023
- | Trial completion, Trial completion date: Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 4, 2022
P2, N=66, Completed, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: May 2023 --> Dec 2023 Active, not recruiting --> Completed | Trial completion date: Aug 2022 --> Nov 2021
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Journal: Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer. (Pubmed Central) - Aug 4, 2022
Active, not recruiting --> Completed | Trial completion date: Aug 2022 --> Nov 2021 FOLFIRINOX and nal-IRI/FL as second-line therapy after GnP provided similar prognoses, although supportive treatment and dose reduction were more frequently required for FOLFIRINOX.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Normaly would use It as 3rd line mostly single agente but had done FOLFIRI a couple of times (Twitter) - Aug 3, 2022
- || FOLFOX + nivo >> paclitaxel + Ramu >> FOLFIRI 3rd L (Twitter) - Aug 3, 2022
- || oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy, Metastases: COLUMBIA 1: COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC (clinicaltrials.gov) - Aug 3, 2022
P1b/2, N=61, Active, not recruiting, Sponsor: MedImmune LLC
FOLFIRINOX and nal-IRI/FL as second-line therapy after GnP provided similar prognoses, although supportive treatment and dose reduction were more frequently required for FOLFIRINOX. Trial completion date: Feb 2024 --> Oct 2023 | Trial primary completion date: Feb 2024 --> Oct 2023
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Trial primary completion date, IO biomarker: AIO-STO-0417: Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - Aug 3, 2022
P2, N=262, Active, not recruiting, Sponsor: Institut f
Trial completion date: Feb 2024 --> Oct 2023 | Trial primary completion date: Feb 2024 --> Oct 2023 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2022 --> Dec 2022
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical: Hmmm - personally, I tend to use irinotecan second line (i.e. FOLFIRI + ram) (Twitter) - Aug 3, 2022
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Clinical data, Retrospective data, Journal, Monotherapy: Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer. (Pubmed Central) - Aug 3, 2022
Conclusion S-1 and mFFX were both acceptable second-line chemotherapies after GnP therapy for UPC, although attention should be paid to myelosuppression during mFFX treatment. Further studies involving nanoliposomal irinotecan plus 5-fluorouracil/leucovorin therapy are necessary to facilitate the selection of the optimal regimen for each patient.
- | Trial completion date, Trial primary completion date: Evaluation of a Folic Acid Wound Treatment (FAWT) for Chronic, Early-Stage Diabetic Foot Ulcer (DFU) Healing (clinicaltrials.gov) - Aug 3, 2022
P2, N=30, Recruiting, Sponsor: Joseph Boykin, MD
Further studies involving nanoliposomal irinotecan plus 5-fluorouracil/leucovorin therapy are necessary to facilitate the selection of the optimal regimen for each patient. Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jul 2022 --> Dec 2022
- | Trial completion date, Trial termination, Trial primary completion date: Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Aug 3, 2022
P2, N=24, Terminated, Sponsor: Albert Einstein College of Medicine
Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jul 2022 --> Dec 2022 Trial completion date: Jun 2022 --> Nov 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2022 --> Nov 2021; Study was terminated due to slower than anticipated accrual
- ||| Yidafan (ivonescimab) / Akesobio, Summit Therapeutics, ligufalimab (AK117) / Akesobio
Enrollment open: AK112-206: A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 3, 2022
P2, N=114, Recruiting, Sponsor: Akeso
Trial completion date: Jun 2022 --> Nov 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2022 --> Nov 2021; Study was terminated due to slower than anticipated accrual Not yet recruiting --> Recruiting
- | 5-fluorouracil / Generic mfg.
Journal: Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment. (Pubmed Central) - Aug 3, 2022
Five out of ten CTx-naïve PDO lines exhibited a differential response to either the FOLFIRINOX or the Gem/Pac regimen...Drug testing of CTx-naïve PDAC PDOs and neoCTx-PDOs may be useful to guide neoadjuvant and adjuvant regimen selection, respectively. Personalizing poly-chemotherapy regimens by omitting substances with low efficacy could potentially result in less-severe side effects, thereby increasing the fraction of patients receiving a full course of neoadjuvant treatment.
- | irinotecan / Generic mfg.
Journal: Clinical Study on Prevention of Irinotecan-Induced Delayed-Onset Diarrhea by Hot Ironing with Moxa Salt Packet on Tianshu and Shangjuxu. (Pubmed Central) - Aug 2, 2022
During the observation period after treatment, the incidence of III°+°IV myelosuppression in the study group was 5.00% (3/60) which is lower than 25.00% (15/60) in the control group (P < 0.05). The hot ironing with moxa salt packet on Tianshu and Shangjuxu was more effective in preventing IIDD, which could reduce the incidence and severity of IIDD, shorten the duration of diarrhea and significantly increase the quality of life of patients with no significant adverse effects.
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical: Neoadjuvant RT After (m)FOLFIRINOX for Borderline Resectable #PDAC: A TAPS Consortium Study: https://t.co/dWgXGDnqXr #PancSM @EileenMOReilly @RadDocMReyngold @MarcBesselink @mkatzmd @CDTzeng @AmerZureikatMD @basgrootkoerkam @wei_ac @craneMSKCC @Caspervaneijck @free_radical28 (Twitter) - Aug 2, 2022
- Multi-Institutional Comparison of Ablative Radiation Therapy in 5 Versus 15-25 Fractions for Locally Advanced Pancreatic Cancer (Henry B. Gonzalez Convention Center, Room 301) - Aug 1, 2022 - Abstract #ASTRO2022ASTRO_2541;
In appropriately selected LAPC patients, ablative RT (BED10 ~100 Gy) in 5 fractions delivered with MR guidance and online adaptive replanning or 15-25 fractions delivered with CT guidance and selective offline adaptive replanning both appear to achieve excellent efficacy and minimal severe toxicity. Choice of fractionation scheme should be based on anatomical considerations and available technology.
- galunisertib (LY2157299) / Eli Lilly
A Phase II Trial of TGFβ Type I Receptor Inhibitor, Galunisertib, plus Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer (Henry B. Gonzalez Convention Center, Room 301) - Aug 1, 2022 - Abstract #ASTRO2022ASTRO_2537;
P2
The addition of TGFβ inhibition to neoadjuvant chemoradiation in locally advanced rectal cancer markedly improved response to therapy, was well tolerated, and warrants further investigation. Clinical Trial Information: NCT02688712.
- Primary Tumor-Directed MRI-Guided Ablative Radiation Therapy for Patients with Metastatic Pancreatic Adenocarcinoma (Henry B. Gonzalez Convention Center, Exhibit Hall 1) - Aug 1, 2022 - Abstract #ASTRO2022ASTRO_1388;
Some metastatic pancreatic cancer patients with stable or chemotherapy-responsive disease appear to benefit from aggressive local therapy which may mitigate morbidity of primary tumor progression. Further investigation into the optimal patient selection for this treatment is warranted.